Literature DB >> 34062473

Comparison of biparametric versus multiparametric prostate MRI for the detection of extracapsular extension and seminal vesicle invasion in biopsy naïve patients.

Iztok Caglic1, Nikita Sushentsev2, Nimish Shah3, Anne Y Warren4, Benjamin W Lamb5, Tristan Barrett6.   

Abstract

PURPOSE: To compare biparametric MRI (bpMRI) with multiparametric MRI (mpMRI) staging accuracy in assessing extracapsular extension (ECE) and seminal vesicle invasion (SVI).
METHOD: Biopsy-naïve patients undergoing 3 T-MRI before radical prostatectomy for clinically significant prostate cancer were included in this single-centre retrospective study. Two uroradiologists separately evaluated bpMRI and mpMRI for presence of ECE and SVI using a 5-point Likert scale (1: ECE/SVI highly unlikely, 5: ECE/SVI highly likely).
RESULTS: 110 men of median age 63 years and PSA 8.5 ng/mL were included. ECE and SVI was confirmed histologically in 71/110 (64.5 %) and 18/110 (16.4 %) patients, respectively. Sensitivity and specificity of bpMRI versus mpMRI for predicting ECE was 59.1 % and 87.2 % versus 66.2 % and 84.6 %, respectively. For SVI detection, the sensitivity and specificity for bpMRI versus mpMRI was 66.7 % and 92.4 % versus 83.3 % and 97.8 %, respectively. At an optimal cut-off Likert score ≥3 for ECE prediction, mpMRI area under the receiver operating curve (AUC) was 0.80 (95 % confidence interval (CI) 0.72-0.87) versus 0.78 (95 % CI 0.69-0.86) for bpMRI (p = 0.52) and for SVI, mpMRI AUC was 0.91 (95 % CI 0.84-0.96) versus 0.86 (95 % CI 0.78-0.92) for bpMRI (p = 0.02), respectively. Inter-reader agreement for both ECE and SVI prediction was substantial, with a marginally higher k-value for mpMRI (k range, 0.67-0.75) than bpMRI (k range, 0.65-0.69).
CONCLUSIONS: Diagnostic performance of bpMRI and mpMRI was comparable for detection of ECE, however, mpMRI with contrast was superior for SVI detection and improved the inter-reader agreement.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Diffusion weighted imaging; Dynamic contrast enhancement; Magnetic resonance imaging; Prostate cancer; Tumour staging

Year:  2021        PMID: 34062473     DOI: 10.1016/j.ejrad.2021.109804

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

Review 1.  Is perfect the enemy of good? Weighing the evidence for biparametric MRI in prostate cancer.

Authors:  Alexander P Cole; Bjoern J Langbein; Francesco Giganti; Fiona M Fennessy; Clare M Tempany; Mark Emberton
Journal:  Br J Radiol       Date:  2021-12-16       Impact factor: 3.039

2.  Biparametric prostate MRI: impact of a deep learning-based software and of quantitative ADC values on the inter-reader agreement of experienced and inexperienced readers.

Authors:  Stefano Cipollari; Martina Pecoraro; Alì Forookhi; Ludovica Laschena; Marco Bicchetti; Emanuele Messina; Sara Lucciola; Carlo Catalano; Valeria Panebianco
Journal:  Radiol Med       Date:  2022-09-17       Impact factor: 6.313

3.  Negative mpMRI Rules Out Extra-Prostatic Extension in Prostate Cancer before Robot-Assisted Radical Prostatectomy.

Authors:  Eoin Dinneen; Clare Allen; Tom Strange; Daniel Heffernan-Ho; Jelena Banjeglav; Jamie Lindsay; John-Patrick Mulligan; Tim Briggs; Senthil Nathan; Ashwin Sridhar; Jack Grierson; Aiman Haider; Christos Panayi; Dominic Patel; Alex Freeman; Jonathan Aning; Raj Persad; Imran Ahmad; Lorenzo Dutto; Neil Oakley; Alessandro Ambrosi; Tom Parry; Veeru Kasivisvanathan; Francesco Giganti; Greg Shaw; Shonit Punwani
Journal:  Diagnostics (Basel)       Date:  2022-04-23

Review 4.  Current Opinion on the Use of Magnetic Resonance Imaging in Staging Prostate Cancer: A Narrative Review.

Authors:  Jamie Michael; Kevin Neuzil; Ersan Altun; Marc A Bjurlin
Journal:  Cancer Manag Res       Date:  2022-03-01       Impact factor: 3.989

Review 5.  Diffusion-Weighted MRI in the Genitourinary System.

Authors:  Thomas De Perrot; Christine Sadjo Zoua; Carl G Glessgen; Diomidis Botsikas; Lena Berchtold; Rares Salomir; Sophie De Seigneux; Harriet C Thoeny; Jean-Paul Vallée
Journal:  J Clin Med       Date:  2022-03-30       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.